Signet Therapeutics gets a $10M top-up for next-gen cancer bets

Little U.S.-China startup Signet Therapeutics has bagged a second seed round worth around $10 million as plots a path to the clinic.

The new round was led by 5Y Capital (Morningside Venture) with help from Yael Capital and Blue Ocean Capital as well as existing investors Tiantu Capital and Sky9 Capital.